These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 16320119)

  • 1. Progressive neurodegenerative disease and pain.
    Shah S; Tear S
    IDrugs; 2005 Dec; 8(12):957-9. PubMed ID: 16320119
    [No Abstract]   [Full Text] [Related]  

  • 2. The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain.
    Westaway SM
    J Med Chem; 2007 May; 50(11):2589-96. PubMed ID: 17489570
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway.
    Gunthorpe MJ; Chizh BA
    Drug Discov Today; 2009 Jan; 14(1-2):56-67. PubMed ID: 19063991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept.
    Szallasi A; Cortright DN; Blum CA; Eid SR
    Nat Rev Drug Discov; 2007 May; 6(5):357-72. PubMed ID: 17464295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model.
    Gomtsyan A; Bayburt EK; Keddy R; Turner SC; Jinkerson TK; Didomenico S; Perner RJ; Koenig JR; Drizin I; McDonald HA; Surowy CS; Honore P; Mikusa J; Marsh KC; Wetter JM; Faltynek CR; Lee CH
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3894-9. PubMed ID: 17507218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New analgesics coming. Monoclonal NGF antibody takes the lead].
    Claesson A
    Lakartidningen; 2009 Feb 11-17; 106(7):430-4. PubMed ID: 19350769
    [No Abstract]   [Full Text] [Related]  

  • 7. [Neurodegenerative disorders: the role of genetic factors in their origin and the efficiency of treatment].
    Sukhanov VA; Ionov ID; Piruzian LA
    Fiziol Cheloveka; 2005; 31(4):119-30. PubMed ID: 16122046
    [No Abstract]   [Full Text] [Related]  

  • 8. TRPV1: a therapeutic target for novel analgesic drugs?
    Szallasi A; Cruz F; Geppetti P
    Trends Mol Med; 2006 Nov; 12(11):545-54. PubMed ID: 16996800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coenzyme Q treatment of neurodegenerative diseases of aging.
    Galpern WR; Cudkowicz ME
    Mitochondrion; 2007 Jun; 7 Suppl():S146-53. PubMed ID: 17485247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks.
    Wong GY; Gavva NR
    Brain Res Rev; 2009 Apr; 60(1):267-77. PubMed ID: 19150372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders.
    Neff F; Wei X; Nölker C; Bacher M; Du Y; Dodel R
    Autoimmun Rev; 2008 Jun; 7(6):501-7. PubMed ID: 18558370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific neuroimmunophilin ligands to treat neurodegenerative disease.
    Fletcher L
    Mol Med Today; 1997 Dec; 3(12):518. PubMed ID: 9449119
    [No Abstract]   [Full Text] [Related]  

  • 13. Challenges faced in choosing novel targets to treat chronic pain.
    Henze DA
    Future Med Chem; 2009 May; 1(2):231-5. PubMed ID: 21425964
    [No Abstract]   [Full Text] [Related]  

  • 14. A 74-year-old woman with progressive right-hand tremor and inability to use her right side.
    Kertesz A; Fealey RD; Keegan BM; Parisi JE
    Neurology; 2009 Oct; 73(17):1399-405. PubMed ID: 19858463
    [No Abstract]   [Full Text] [Related]  

  • 15. Transgenic animal models of neurodegenerative diseases and their application to treatment development.
    Rockenstein E; Crews L; Masliah E
    Adv Drug Deliv Rev; 2007 Sep; 59(11):1093-102. PubMed ID: 17869376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From arylureas to biarylamides to aminoquinazolines: discovery of a novel, potent TRPV1 antagonist.
    Zheng X; Hodgetts KJ; Brielmann H; Hutchison A; Burkamp F; Brian Jones A; Blurton P; Clarkson R; Chandrasekhar J; Bakthavatchalam R; De Lombaert S; Crandall M; Cortright D; Blum CA
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5217-21. PubMed ID: 16870426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pain therapeutics--SMi's seventh annual conference. 12-13 June 2006, London, UK.
    Harrop S
    IDrugs; 2006 Aug; 9(8):548-50. PubMed ID: 16871462
    [No Abstract]   [Full Text] [Related]  

  • 18. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.
    Honore P; Chandran P; Hernandez G; Gauvin DM; Mikusa JP; Zhong C; Joshi SK; Ghilardi JR; Sevcik MA; Fryer RM; Segreti JA; Banfor PN; Marsh K; Neelands T; Bayburt E; Daanen JF; Gomtsyan A; Lee CH; Kort ME; Reilly RM; Surowy CS; Kym PR; Mantyh PW; Sullivan JP; Jarvis MF; Faltynek CR
    Pain; 2009 Mar; 142(1-2):27-35. PubMed ID: 19135797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection.
    Vamos E; Pardutz A; Klivenyi P; Toldi J; Vecsei L
    J Neurol Sci; 2009 Aug; 283(1-2):21-7. PubMed ID: 19268309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain.
    Culshaw AJ; Bevan S; Christiansen M; Copp P; Davis A; Davis C; Dyson A; Dziadulewicz EK; Edwards L; Eggelte H; Fox A; Gentry C; Groarke A; Hallett A; Hart TW; Hughes GA; Knights S; Kotsonis P; Lee W; Lyothier I; McBryde A; McIntyre P; Paloumbis G; Panesar M; Patel S; Seiler MP; Yaqoob M; Zimmermann K
    J Med Chem; 2006 Jan; 49(2):471-4. PubMed ID: 16420034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.